Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 6/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398949 | 0.86 | CCR1 (0.59) | CCR1CNR1CNR2NPSR1MAPK1 | |
| SCHEMBL2401015 | 0.82 | CCR1 (0.67) | CCR1CNR1CNR2NPSR1PTGER4 | |
| SCHEMBL2400278 | 0.79 | CCR1 (0.57) | CCR1NPSR1NPC1RAB9AP2RX7 | |
| SCHEMBL2401057 | 0.78 | CCR1 (0.54) | CCR1CNR1CNR2 | |
| SCHEMBL2398963 | 0.76 | CCR1 (0.52) | CCR1CNR1CNR2NPC1RAB9A | |
| SCHEMBL2399482 | 0.76 | CCR1 (0.69) | CCR1CNR1NPSR1NPC1RAB9A | |
| SCHEMBL2399393 | 0.75 | CCR1 (0.49) | CCR1CNR1CNR2NPC1RAB9A | |
| SCHEMBL2402829 | 0.75 | CCR1 (0.51) | CCR1CNR1CNR2NPSR1NPC1 | |
| SCHEMBL1575018 | 0.74 | MAPK1 (0.61) | CCR1NPSR1MAPK1NPC1RAB9A | |
| SCHEMBL2402900 | 0.74 | NOTUM (0.57) | CCR1MAPK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297112-B1 | PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2013-04-03 | — | — | EP | disclosed |
| US-8293917-B2 | Pyrazole compounds as CCR1 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-8293917-B2 | Pyrazole compounds as CCR1 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110230521-A1 | Pyrazole Compounds As CCR1 Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230521-A1 | Pyrazole Compounds As CCR1 Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230521-A1 | Pyrazole Compounds As CCR1 Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| WO-2009137338-A1 | PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230521-A1 | Pyrazole Compounds As CCR1 Antagonists | CCR1, CCR3, CCR4 | CCR1 1/4885CNR1 23/4885CNR2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.